Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Assets (2016 - 2025)

Lexaria Bioscience's Assets history spans 11 years, with the latest figure at $6.1 million for Q4 2025.

  • For Q4 2025, Assets fell 38.22% year-over-year to $6.1 million; the TTM value through Nov 2025 reached $6.1 million, down 38.22%, while the annual FY2025 figure was $4.2 million, 52.92% down from the prior year.
  • Assets for Q4 2025 was $6.1 million at Lexaria Bioscience, up from $4.2 million in the prior quarter.
  • Across five years, Assets topped out at $13.3 million in Q3 2021 and bottomed at $63573.0 in Q2 2024.
  • The 5-year median for Assets is $7.3 million (2022), against an average of $6.5 million.
  • The largest annual shift saw Assets plummeted 99.26% in 2023 before it soared 12745.14% in 2024.
  • A 5-year view of Assets shows it stood at $11.7 million in 2021, then tumbled by 49.91% to $5.9 million in 2022, then crashed by 98.7% to $76245.0 in 2023, then skyrocketed by 12745.14% to $9.8 million in 2024, then tumbled by 38.22% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Assets are $6.1 million (Q4 2025), $4.2 million (Q3 2025), and $6.7 million (Q2 2025).